| Project/Area Number |
17K16495
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | National Institutes for Quantum and Radiological Science and Technology |
|---|
Principal Investigator |
XIE Lin 国立研究開発法人量子科学技術研究開発機構, 放射線医学総合研究所 先進核医学基盤研究部, 主任研究員(定常) (30623558)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | TSPO / 先制医療 / 肝疾患 / PET診断 / PET診断法 |
|---|
| Outline of Final Research Achievements |
Recently we developed a novel noninvasive approach for diagnosing steatohepatitis, namely [18F]FEDAC-PET, based on visualizing the translocator protein (18 kDa)(TSPO)-a mitochondrial transmembrane protein. To explore the feasibility of the imaging strategy in clinical practice, we here evaluated and quantified the TSPO expression and [18F]FEDAC binding density in 50 human liver subjects. Our results showed the expression of TSPO protein was much higher in steatohepatitis than in not steatohepatitis, with increasing [18F]FEDAC binding density. We also found for the first time a close correlation in human liver subjects between liver pathological scores and TSPO level, [18F]FEDAC binding density. This study demonstrated [18F]FEDAC-PET can serve as noninvasive diagnostic method to identify patients with steatohepatitis with sufficient accuracy to be considered for clinical use.
|
| Academic Significance and Societal Importance of the Research Achievements |
これまでに、我々は進行性脂肪肝疾患マウスに対し、発症及び病気進展の先行指標である蛋白質TSPOをバイオマーカーとして特定した上で、TSPOに特異的な分子プローブ[18F]FEDACを開発し、PETでTSPOを可視化することにより、世界で初めて脂肪肝疾患の進行度を判定できる非侵襲的なPET診断法の開発に成功した。今回の研究は、ヒト肝臓を用いたことにより、TSPO及び[18F]FEDAC-PETの有用性を明らかにすることで、肝疾患におけるTSPO-PET診断法が臨床実用化へ加速することはより一層期待される。
|
